The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Patient and hematologist treatment preferences in CLL: insights from a European qualitative study
Talha Munir, MBBS, MRCP, FRCPath, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the findings of a qualitative study on treatment-characteristic preferences among people with chronic lymphocytic leukemia (CLL) and hematologists in Europe. Dr Munir highlights that while patients and clinicians prioritize treatment effectiveness, they diverge on concerns such as common side effects and long-term effectiveness, and emphasizes the importance of considering these preferences in treatment conversations. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
